

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort NeuroScientific Corporation

微創腦科學有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2172)

POSITIVE PROFIT ALERT

This announcement is made by MicroPort NeuroScientific Corporation (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company is pleased to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group and other currently available information for the year ended 31 December 2024 (the “**Reporting Period**”), the net profit of the Group is expected to be ranged from approximately RMB236 million to RMB270 million, representing an increase of approximately 75% to 100% as compared to that of the corresponding period of last year. From 2020 to 2024, the Group achieved an adjusted net profit¹, demonstrating a 5-year compound annual growth rate (CAGR) of approximately 55%.

Based on currently available information, the Board considers that the aforementioned expected increase in the profit of the Group is principally attributable to the following reasons:

- (1) Benefited from the increment in hospital coverage and market share, as well as the twofold increase in the revenue from our oversea business, it is expected that the Group’s revenue for the Reporting Period will attain a two-digit growth;

¹ The Company used “adjusted net profit” as non-HKFRS measures, eliminating impacts of profit or loss of associates and certain non-operational items and non-cyclical or one-time expense items (including accrued interest expenses on preferred shares, listing expenses, share-based payment expenses and potential impairment loss on assets, etc.).

- (2) Through implementation of supply chain improvement and cost-saving measures, the Group has boosted its operating efficiency, resulting in a significant increase in profitability.

As at the date of this announcement, the Company is still in the process of preparing and finalizing the annual results of the Group for the year ended 31 December 2024 (the “**2024 Annual Results**”). The information contained in this announcement is only a preliminary assessment made by the Board based on the latest management accounts of the Group which have not been audited or reviewed by the independent auditors or the audit committee of the Company. Shareholders and potential investors of the Company are advised to read the Company’s announcement of the 2024 Annual Results carefully, which is expected to be published by the end of March 2025.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
MicroPort NeuroScientific Corporation
Dr. Chang Zhaohua
Chairman

Hong Kong, 12 January 2025

As at the date of this announcement, Mr. Xie Zhiyong and Mr. Wang Yiqun Bruce are the executive Directors; Dr. Chang Zhaohua, Mr. Sun Qingwei, Mr. Wang Lin and Ms. Wu Xia are the non-executive Directors; and Dr. Xu Yi, Dr. Zhang Haixiao, and Mr. Fan Xin are the independent non-executive Directors.